Table 2 Participants’ characteristics
Stakeholder group | Country | Type of institution | Participant number |
|---|---|---|---|
Academic trialists | USA | University | 1 |
Australia | University | 2 | |
The Netherlands | University | 3 | |
Canada | University | 9 | |
USA | University | 10 | |
Industry trialists | USA | Research institute | 4 |
USA | Research institute | 5 | |
UK | Pharmaceutical company | 11 | |
USA | Pharmaceutical company | 16 | |
USA | Global contract research organisation | 17 | |
Journal editors | USA | Peer-reviewed medical journal | 7 |
UK | Peer-reviewed medical journal | 15 | |
USA | Peer-reviewed medical journal | 24 | |
Clinicians | USA | University | 1* |
UK | Government | 8* | |
Canada | University | 9* | |
UK | Charity | 18* | |
USA | Funding institute | 19* | |
UK | University | 23 | |
UK | University | 24* | |
Policy-makers and regulators | USA | Regulatory agency | 6 |
UK | Regulatory agency | 8 | |
Germany | Reimbursement agency | 12 | |
UK | Regulatory agency | 13 | |
UK | Reimbursement agency | 14 | |
Funders | UK | Charity | 18 |
USA | Funding institute | 19 | |
UK | Government | 20 | |
USA | Funding institute | 21 | |
USA | Funding institute | 22 |